Rituximab (anti-CD20 mAb), trastuzumab (anti-Her2/neu mAb), and cetuximab [anti-epidermal growth factor receptor (EGFR) mAb] represent just some examples of mAbs with demonstrated efficacy in the treatment of B-cell non-Hodgkin lymphoma (NHL), Her2+ breast cancers, colorectal carcinoma, and head and neck cancers, respectively (25, 26). This evidence concerns the gene EGFR and non-Hodgkin lymphoma.